ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114

Oric Pharmaceuticals, Inc.

Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.
Two private placements raised $85M (June 2023) and $125M (Jan 2024); pro forma cash $351.8M at Jan 31, 2024, funding into late 2026.
Initial Phase 1b data for ORIC-114 (EGFR/HER2) and ORIC-944 (PRC2) show best-in-class potential; dose expansion for ORIC-114 in mutated NSCLC expected H1 2024.
ORIC-533 (CD73 inhibitor) Phase 1b dose escalation completed Q1 2024; company plans strategic partnership for combination studies.
ORIC-944 combination study with AR inhibitor to start H1 2024; program update mid-2024. Discovery includes PLK4 inhibitor ORIC-613 advancing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Oric Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 11, 2024, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.